The Cutaneous Connection The Cutaneous Connection

James Song, MD, FAAD, chief medical officer and director of clinical research at Frontier Dermatology in Seattle, Washington, delves into the complexities and advancements in treating atopic dermatitis (AD). Song highlights the challenges of transitioning patients from topical to systemic therapies, emphasizing the need for timely conversations and patient comfort. He discusses the efficacy and rapid response of oral JAK inhibitors compared to biologics, while addressing safety concerns and the necessity for blood monitoring. Song also explores patient-specific factors in treatment choices, the importance of systemic therapy for moderate to severe cases, and the promise of emerging biologics targeting IL-31 and OX40 pathways. This episode is a comprehensive guide for dermatology clinicians navigating the evolving landscape of AD treatments. 

In today’s episode, Nanette Silverberg reviews the key highlights from her vitiligo sessions at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, also known this year as RAVE. Dr. Silverberg is the chief of pediatric dermatology for the Mount Sinai Health System and site director of pediatric and adolescent dermatology at Mount Sinai West and Mount Sinai Beth Israel in New York, as well as the conference chair of the vitiligo portion of RAVE. At the conference, Dr. Silverberg presented “Topical Therapeutics for Vitiligo” and “Excellence in Vitiligo Clinical Practice.” Today, Dr. Silverberg shares the top takeaways from her sessions that clinicians can utilize in their practice. 

Bradley Burnam, the founder and CEO of Turn Therapeutics, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of Hexagen technology and its potential in eczema, onychomycosis, and more.

Brian Kim, MD, had an unexpected attendee at one of his AAD sessions and delves into what's new, what's now, and what's next in atopic dermatitis management.

Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut and Dermatology Times Editorial Advisory Board Member, caught up with us at the 2024 American Academy of Dermatology Meeting to decode new atopic dermatitis treatment data and how that translates to personalized options for patients.

Raj Chovatiya, MD, PhD, gives a sneak peek of what to expect in atopic dermatitis education at the 2024 American Academy of Dermatology (AAD) Meeting in San Diego, California March 8-12. Since the last meeting, the AAD has released new guidelines to treat the condition.